Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States
MLS to market Biocept's proprietary liquid biopsy testing platform in key sales territories, with potential to expand the agreement in the future
View HTML
Toggle Summary Biocept Launches Liquid Biopsy Test for NRAS Mutations
Expands commercial offering to 15 clinically actionable biomarker tests, including key validated alterations listed in the NCCN Guidelines® for metastatic melanoma and colorectal cancer
View HTML
Toggle Summary Biocept to Present at the 6th Annual Gateway Conference on September 6, 2017 in San Francisco
SAN DIEGO , Aug. 28, 2017 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that President and CEO Michael W.
View HTML
Toggle Summary Biocept and UT Southwestern Medical Center Announce Clinical Study to Profile and Monitor Non-Small Cell Lung Cancer Patients with ALK Rearrangements
Leading clinical investigator to utilize Biocept's liquid biopsy tests for the detection of ALK rearrangements at baseline and to monitor treatment response and resistance mechanisms over time
View HTML
Toggle Summary Biocept Enters Into Exclusive Distribution Agreement with Global Laboratory Product Supplier VWR
Patented blood collection tubes developed by Biocept validated to preserve ctDNA for up to 96 hours at room temperature allowing for intact shipping of liquid biopsy samples from regions around the world
View HTML
Toggle Summary Biocept Reports Second Quarter 2017 Financial Results
- Reported revenues of $1.3 million in 2Q 2017 vs. $663,000 in 2Q 2016, up 93%, or 64% excluding the impact of conversion to accrual-based revenue recognition- Launch of "AND" campaign supports growth in test volume both sequentially and year-over-year- New provider agreements with both Scripps Health Plan and MediNcrease expand patient access to Biocept's proprietary liquid biopsy test platform- Secures $2.2 million investment from Ally Bridge LB Healthcare Master Fund- Evaluating strategic opportunities in China with Ally Bridge's Chinese affiliate- Company to host conference call at 4:30 p.m. Eastern time today
View HTML
Toggle Summary Biocept Announces Private Placement of $2.2 Million of Common Stock with Ally Bridge LB Healthcare Master Fund
Biocept and Ally Bridge to evaluate strategic opportunities in China for the Company's liquid biopsy platform
View HTML
Toggle Summary Biocept Executes Preferred Provider Agreement with Scripps Health Plan Expanding Patient Coverage for its Liquid Biopsy Platform
Prestigious Southern California health plan contracts with Biocept to make the Company's Target Selector™ tests available in-network for its patients with cancer
View HTML
Toggle Summary Biocept to Release Second Quarter 2017 Financial Results and Host Investor Conference Call on August 10, 2017
SAN DIEGO , Aug. 3, 2017 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it will release financial results for the
View HTML
Toggle Summary Biocept Expands Commercial Offering of Clinically Actionable Biomarker Assays with Launch of Liquid Biopsy Test for Progesterone Receptor Detection
Biocept now offers 14 clinically actionable biomarker tests, including all validated biomarkers for breast cancer in NCCN Guidelines®
View HTML